Applied DNA Sciences

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment consists of the manufacture of DNA for use in nucleic acid-based therapeutics. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Applied DNA Sciences reports strong Q1 results and eyes revenue diversification

Applied DNA Sciences demonstrated robust revenue growth and operational improvements in Q1 2023, driven by key revenue streams and cost management.
While facing financial challenges and dependency on key projects for guidance, the company is strategically positioned for growth and innovation.
Opportunities in nucleic acid therapies, strategic partnerships, and revenue diversification present a promising outlook for Applied DNA Sciences.

Applied DNA Sciences adapts focus to genomics amid revenue challenges

Applied DNA Sciences faced revenue challenges in Q2 2023 but showcased resilience through strategic focus on pharma genomics testing and DNA tagging solutions.
The company's emphasis on efficiency in mRNA manufacturing and pursuit of acquisitions signal a proactive approach to enhancing market competitiveness and technological capabilities.
While financial challenges persist, opportunities in genetic testing and compliance solutions position Applied DNA Sciences for future growth and market leadership.

Applied DNA Sciences reports revenue decline and operational challenges

Applied DNA Sciences faced challenges in revenue decline and increased operating expenses in Q3 2023, leading to an operating loss and concerns about its financial sustainability.
Despite these challenges, the company demonstrated strengths in enhancing mRNA initiatives through the Spindle Biotech acquisition and Linea IVT platform, as well as continued growth in supply chain traceability.
Opportunities lie in expanding partnerships with evaluation customers, leveraging the Linea IVT platform's capabilities, and exploring new revenue streams in DNA tagging applications.

Applied DNA Sciences reports Q4 revenue decline, focuses on growth

Applied DNA Sciences faced a challenging quarter with declining revenues and operating losses, but maintained a focus on innovation and growth.
The company's strategic strengths lie in biotherapeutic manufacturing, successful acquisitions, and plans for revenue expansion through the Linea IVT platform.
However, challenges such as Nasdaq compliance issues and financial pressures require careful management and strategic decision-making.
Opportunities for revenue growth and market expansion exist through customer relationships, product development, and addressing regulatory requirements.

Applied DNA Sciences tackles financial challenges while eyeing revenue growth

Applied DNA Sciences faces challenges with declining revenues and profitability, necessitating a focus on cost management and revenue generation to improve financial health.
Despite financial pressures, the company's strategic strengths lie in innovative product development, quality control measures, and efforts to enhance operational efficiency.
Opportunities for revenue growth exist through the commercialization of Linea IVT platform, international expansion, and partnerships, signaling potential for market expansion and increased customer adoption.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied DNA Sciences, Inc. engages in developing and marketing technologies to produce and detect deoxyribonucleic acid. It operates through the following segments: Therapeutic DNA Production, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production segment offers DNA detection via PCR to provide and develop clinical molecular diagnostics and genetic testing services. The MDx Testing Services segment is involved in performing and developing clinical molecular diagnostic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment includes manufacture and detection of DNA for industrial supply chain security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.

Seeking Alpha Transcripts | Healthcare Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2020 Results - Earnings Call Transcript Dec. 17, 2020 10:09 PM ET | | About: Applied DNA Sciences, Inc. (APDN) by: SA Transcripts Subscribers Only Earning Call Audio Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2020 Earnings Conference Call December 17, 2020 4:30 PM ET Corporate Participants Sanjay Hurry - Executive Director of Investor Relations and Corporate Communications James Hayward - Chairman, President and Chief Executive Officer

Applied DNA Sciences, Inc. (APDN) CEO James Hayward on Q4 2020 Results - Earnings Call Transcript

Applied DNA Sciences (APDN) delivered earnings and revenue surprises of -38.98% and -55.14%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Applied DNA Sciences (APDN) Reports Q4 Loss, Misses Revenue Estimates

Shares of Applied DNA Sciences (NASDAQ:APDN) fell 21.15% after the company reported Q4 results. Quarterly Results Earnings per share rose 43.06% year over year to ($0.82), which missed the estimate of ($0.52).

Recap: Applied DNA Sciences Q4 Earnings

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2020. “Our activities in fiscal 2020 were principally devoted to the establishment of our diagnostic and surveillance testing programs for COVID-19 and to further positioning our proprietary LinearDNA™ manufacturin

Applied DNA Reports 2020 Year End and Fiscal Fourth Quarter Financial Results

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (ADCL), has secured a safeCircle™ pooled COVID-19 surveillance testing program (the “Program”) award with a potential value of up to $2.0 million from the Suffolk County (N.Y.) Government (the “County”). The 6-month term and awar

Applied DNA Awarded Pooled Surveillance Testing Contract Valued at Up to $2.0 Million from Suffolk County (N.Y.) Government

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its Applied DNA Clinical Laboratories, LLC (ADCL) subsidiary is experiencing growing demand for its safeCircle™ pooled COVID-19 surveillance testing program that is being primarily driven by New York State (the “State”) schools moving to comply with the State's Winter COVID-19 Plan (the “Plan”) that al

Compliance with New York State Winter COVID-19 Plan Drives Demand for Applied DNA's Pooled Surveillance Testing Program

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it will release financial results for its fiscal 2020 fourth quarter ended September 30, 2020 after market close on Thursday, December 17, 2020. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Standard Time that will also be broadcast live over th

Applied DNA Schedules Fiscal 2020 Fourth Quarter Financial Results Conference Call for Thursday, December 17, 2020 at 4:30 PM EST

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the expansion of commercial activities under its multi-year Master Services Agreement (MSA) with Nutrition21 whereby Nutrition21 has transitioned to Applied DNA's CertainT® platform to secure its IP-protected portfolio of dietary supplement ingredients. Concurrently, the Company received two follow-on

Nutrition21 Transitions to Applied DNA's CertainT® Platform to Secure IP-protected Portfolio of Dietary Supplement Ingredients

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that its wholly-owned subsidiary, Applied DNA Clinical Laboratories, LLC (“ADCL”), will provide its COVID-19 surveillance testing program to the Stony Brook University Seawolves men's and women's basketball teams. ADCL's pooled surveillance testing platform, known as safeCircle™, will aid the safe return to

Applied DNA to Provide COVID-19 Surveillance Testing to Stony Brook Basketball

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, EvviVax, S.R.L. (“EvviVax”), a spin-off of Takis Biotech with expertise in engineered veterinary cancer immunotherapy and targeted vaccines, and Veterinary Oncology Services at Guardian Veterinary Specialists (GVS), a multi-specialty veterinary hospital, announced the receipt of approvals from the New York State Depa

Applied DNA, EvviVax, and GVS Receive Regulatory Approval to Conduct Veterinary Clinical Trial for Linear COVID-19 Vaccine Candidate

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it is scheduled to participate virtually in the Imperial Capital 2020 Security Investor Conference on Thursday, December 3, 2020. Dr. James A. Hayward, chief executive officer, will present at 10:45 a.m. EST that day and host one-on-one meetings throughout the day. An archived webcast will be available

Applied DNA to Present at the Imperial Capital 2020 Security Investor Conference on December 3

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ:APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that the U.S. Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) amendment that expands the installed base of RT-PCR platforms that can process the Company's Linea™ COVID-19 Assay Kit. The EUA amendment extends the RT-PCR platform authorization from Applied Biosystems' (Therm

Applied DNA Significantly Expands Addressable Market for Linea™ COVID-19 Assay Kit via Successful Amendment to FDA EUA

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has secured a blanket purchase order from an existing customer for its Linea™ COVID-19 Assay Kit (the “Assay Kit”) and consumables to conduct 10,000 tests. The Company has already shipped a portion of the purchase order in the current fiscal quarter ending December 31, 2020. The balance of the

Applied DNA Secures Blanket Purchase Order for 10,000 Linea™ COVID-19 Tests

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc., (NASDAQ: APDN) (“Applied DNA” or the "Company") a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Linea™ COVID-19 Assay Kit (the “Assay Kit”) has been selected by Stony Brook University Hospital (SBUH) for use in SBUH's newly launched COVID-19 surveillance testing program (the “Program”). At peak operations, the Program will utilize frequent pooled testing to enable the early detection an

Stony Brook University Hospital Launches COVID-19 Surveillance Testing Program Powered by Applied DNA's Assay Kit and Services

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #AAV--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it received orders for its linear DNA to be evaluated in an RNA vaccine and Adeno-Associated Virus (AAV) production from two new contract research customers, respectively. The Company also received a follow-on order for linear DNA from an existing contract research customer for a preclinical CAR T ther

Applied DNA Announces Linear DNA Orders from New Contract Research Customers for Use in RNA Vaccine and Adeno-Associated Virus Applications

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables diagnostics in vitro, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting, and anti-theft technology, today announced that it plans to boost its COVID-19 testing capacity at Applied DNA Clinical Laboratories, LLC (“ADCL”), its wholly-owned subsidiary, to

Applied DNA to Increase COVID-19 Surveillance Testing Utility for its Linea™ COVID-19 Assay Kits Through Expanded Use of Robotic Automation

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting, and anti-theft technology, announced that Applied DNA Clinical Laboratories, LLC (“ADCL”), its wholly-owned subsidiary, has secured COVID-19 surveillance testing contracts under i

Applied DNA Secures $1.0+ Million in COVID-19 Surveillance Testing Annualized Revenue, Builds Sales Pipeline for Test Kit and Testing-as-a-Service

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #biotech--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting, and anti-theft technology, today announced that it entered into an agreement (the “Agreement”) with the sole holder (the “Holder”) of its outstanding July 16, 2019, secured conver

Applied DNA Announces Repayment of Secured Convertible Notes

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced the signing of a Master Services Agreement (MSA) with Stony Brook University Hospital (“SBUH”), the largest academic medical center on Lo

Applied DNA Signs Master Services Agreement with Stony Brook University Hospital for COVID-19 Diagnostic Assay Kit and Automated Systems, Receives Initial Purchase Order

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today announced it has entered into a supply agreement (the “Agreement”) for its CertainT® platform with ITW Pillar Technologies (“Pillar”), a division o

Applied DNA Enters into Supply Agreement with ITW Pillar Technologies to Bring CertainT® Platform to Textiles Including Those Used in Personal Protective Equipment

STONY BROOK, N.Y.--(BUSINESS WIRE)---- $APDN #COVID19--Applied DNA Sciences, Inc.

Applied DNA and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate

Applied DNA to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15

Applied DNA Provides Update on Status of New York State Laboratory Permit for Clinical Labs Subsidiary

Applied DNA Positions LinearDNA™ Platform as the Next Generation Manufacturing Platform for Adeno-Associated Virus-based Gene Therapies Through New Patent Filing

News for Applied DNA Sciences Stock (APDN)